Business Description
Candel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1374041093
Description
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.16 | |||||
| Equity-to-Asset | -0.38 | |||||
| Debt-to-Equity | -1.86 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -24.3 | |||||
| 3-Year FCF Growth Rate | -28.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.58 | |||||
| 9-Day RSI | 30.5 | |||||
| 14-Day RSI | 39.79 | |||||
| 6-1 Month Momentum % | -4.51 | |||||
| 12-1 Month Momentum % | 560.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.62 | |||||
| Quick Ratio | 1.62 | |||||
| Cash Ratio | 1.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.8 | |||||
| Shareholder Yield % | -1.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -399.62 | |||||
| ROA % | -120.35 | |||||
| ROIC % | -281.25 | |||||
| ROC (Joel Greenblatt) % | -1150.5 | |||||
| ROCE % | -160.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -4.29 | |||||
| EV-to-Forward-EBIT | -4.1 | |||||
| EV-to-EBITDA | -4.38 | |||||
| EV-to-Forward-EBITDA | -4.12 | |||||
| EV-to-Forward-Revenue | 5897.9 | |||||
| EV-to-FCF | -6.56 | |||||
| Earnings Yield (Greenblatt) % | -23.31 | |||||
| FCF Yield % | -15.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CADL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Candel Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.69 | ||
| Beta | -0.8 | ||
| Volatility % | 350.15 | ||
| 14-Day RSI | 39.79 | ||
| 14-Day ATR ($) | 0.497887 | ||
| 20-Day SMA ($) | 6.96525 | ||
| 12-1 Month Momentum % | 560.43 | ||
| 52-Week Range ($) | 0.66 - 14.3 | ||
| Shares Outstanding (Mil) | 32.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Candel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Candel Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Candel Therapeutics Inc Frequently Asked Questions
What is Candel Therapeutics Inc(CADL)'s stock price today?
The current price of CADL is $6.14. The 52 week high of CADL is $14.30 and 52 week low is $0.66.
When is next earnings date of Candel Therapeutics Inc(CADL)?
The next earnings date of Candel Therapeutics Inc(CADL) is 2024-11-08 Est..
Does Candel Therapeutics Inc(CADL) pay dividends? If so, how much?
Candel Therapeutics Inc(CADL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers